MediSapiens will provided Bayer HealthCare Pharmaceuticals with a new cloud-computing application to analyze and visualize multidimensional genomics data. Bayer says that the software, called OncoGenomics Explorer, will provide it with centralized access to unified global genomics data for utilization across the entire research organization, from target discovery to drug repositioning.

“Big Data is becoming increasingly important in pharmaceutical research. Until now, the lack of software tools that can be adapted to various research environments has limited the full-scale use of this enormous reservoir of available data. OncoGenomics Explorer is our answer to this demand,” says Tommi Pisto, CEO of MediSapiens.

Based on a large unified gene expression database, MediSapiens claims that its platform extends into highly tailored solutions to meet the exact needs of various demanding research environments. 

Previous articleDetecting the “Andromeda Strain” Faster and Cheaper
Next articleObama or Romney: Who’s Better for Biotech?